Yvette Henin
Aventis Pharma
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yvette Henin.
Journal of Biological Chemistry | 2000
Xuguang Li; Marie-Christine Multon; Yvette Henin; Fabien Schweighoffer; Corinne Venot; Juliana Josef; Changhong Zhou; Joyce Lavecchio; Patricia Stuckert; Monika Raab; Abner M. Mhashilkar; Bruno Tocque; Wayne A. Marasco
The MAPK pathway is required for T-cell activation; however, its role in modulating T-cell function following human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. In this report, we investigated whether Grb3-3, an isoform of the Grb2 (growth factorreceptor-bound protein-2) adaptor molecule that is associated with the MAPK pathway, could be involved. We found that Grb3-3, but not its isoform Grb2, is markedly up-regulated in CD4+ peripheral blood mononuclear cells derived from either in vitro HIV-1-infected cultures or HIV-1-infected human subjects. Analysis of HIV-1 gene products indicated that Tat and Nef, both of which have been implicated in modulating T-cell function, can independently induce expression of Grb3-3. By using NFAT/AP-1, AP-1, or NFAT reporter assays, we found that Grb3-3 can potentiate NFAT (but not AP-1) promoter activity in Jurkat T-cells upon engagement of the T-cell receptor and CD28 co-receptor. In addition, potentiation of NFAT by Grb3-3 is substantially suppressed by MEKK1, a kinase that may play an important role in retaining NFAT in the cytoplasm, and by cyclosporin A. Finally, we also found that Grb3-3 potentiates HIV-1 long terminal (LTR) repeat promoter activity following T-cell receptor stimulation, an effect that can be largely suppressed by cyclosporin A. Taken together, this study indicates that Grb3-3 is a cellular factor that can be up-regulated by HIV-1. In addition, Grb3-3 can also function as a positive factor for T-cell activation and, in doing so, may aid in establishing an intracellular environment that can optimally support HIV-1 replication.
Proceedings of the National Academy of Sciences of the United States of America | 1994
Jean-Francois Mayaux; Anne Bousseau; Rudi Pauwels; Thierry Huet; Yvette Henin; Norbert Dereu; Michel Evers; Francoise Soler; Christèle Poujade; E. De Clercq
Journal of Medicinal Chemistry | 1996
Michel Evers; Christèle Poujade; Francoise Soler; Yves Ribeill; Claude James; Yves Lelièvre; Jean-Christophe Gueguen; Daniel Reisdorf; Isabelle Morize; Rudi Pauwels; Erik De Clercq; Yvette Henin; Anne Bousseau; Jean-Francois Mayaux; and Jean-Bernard Le Pecq; Norbert Dereu
Journal of Medicinal Chemistry | 1996
Francoise Soler; Christèle Poujade; Michel Evers; Jean-Christophe Carry; Yvette Henin; Anne Bousseau; Thierry Huet; Rudi Pauwels; Erik De Clercq; Jean-Francois Mayaux; and Jean-Bernard Le Pecq; Norbert Dereu
Archive | 2004
Jesus Benavides; Daniel Boccio; Yvette Henin; Odile Piot-Grosjean
Bioorganic & Medicinal Chemistry Letters | 2003
Michel Evers; Jean-Claude Barriere; Georges Bashiardes; Anne Bousseau; Jean-Christophe Carry; Norbert Dereu; Bruno Filoche; Yvette Henin; Serge Sablé; Marc Vuilhorgne; Serge Mignani
Journal of Medicinal Chemistry | 1997
David R. Adams; Caroline Perez; Michel Maillard; Jean-Claude Florent; Michel Evers; Yvette Henin; Simon Litvak; Laura Litvak; Claude Monneret; David S. Grierson
Archive | 2002
Jesus Benavides; Daniel Boccio; Yvette Henin; Odile Piot-Grosjean
Archive | 2002
Jesus Benavides; Daniel Boccio; Yvette Henin; Odile Piot-Grosjean
Biochemical and Biophysical Research Communications | 2000
Xuguang Li; Marie-Christine Multon; Yvette Henin; Fabien Schweighoffer; Corinne Venot; Joyce Lavecchio; Juliana Josef; Patricia Stuckert; Abner M. Mhashilkar; Bruno Tocque; Wayne A. Marasco